InvestSMART

Monash IVF Group Limited (ASX:MVF)

ALERT: Price-sensitive ASX Announcement for MVF
Current share price for MVF : $0.705 0.02 (2.92%)+
Announcement
Release
26 Feb 2026 10:04AM
Price at Release
$0.685
Full Release
download
Summary
The Monash IVF Group's 1H26 Results Presentation outlines a financial and operational performance marked by a slight revenue dip to $137.9 million and a more significant decline in underlying EBITDA and NPAT by 15.3% and 34%, respectively, compared to 1H25. The group's stimulated cycle volumes decreased by 9.9%, with market share falling by 2.5% to 19.0%. Despite the decline, there are signs of stabilization in the Australian ARS market, and the company has noted growth in genetics and ancillary income. For FY26, the company expects an underlying NPAT of $20.0 million and plans capital expenditures of $16-17 million, with significant investments in new clinic facilities. International operations showed positive growth in patient treatments.
Key Points
  • 1H26 revenue of $137.9 million, down 1.8% from 1H25.
  • 1H26 underlying EBITDA decreased by 15.3% to $30.2 million.
  • 1H26 underlying NPAT was $10.4 million, a decline of 34% from 1H25.
  • 1H26 stimulated cycles decreased by 9.9% compared to 1H25.
  • MVF market share for stimulated cycles decreased by 2.5% to 19.0% in 1H26.
  • The Australian ARS market showed early signs of stabilization with a marginal decline in stimulated cycles.
  • Genetics and ancillary income grew by $2.5 million due to increased PGT activity.
  • FY26 outlook includes expected underlying NPAT of $20.0 million and capital expenditure of $16-17 million.
  • Capital expenditure of $10.0 million in 1H26, including $6.0 million for a new Brisbane clinic.
  • International patient treatments increased by 4.9% in 1H26.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.